Association of Mean Corpuscular Hemoglobin Concentration With Mortality in Patients With Cancer
Related Experiment Video
Updated: Mar 28, 2026
Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
Jing Zhang1, Shaohua Zhang1, Sheng Chen1
1Graduate School, Guangxi University of Chinese Medicine, Nanning, CHN.
Background:
While mean corpuscular hemoglobin concentration (MCHC) correlates with prognosis in various critical conditions, its relationship with mortality in ICU patients with cancer remains underexplored.
Methods:
We included 20,055 cancer patients with available MCHC values. Data extracted included demographics, comorbidities, laboratory parameters within 24 hours, illness severity scores, and vasoactive medication use. Primary outcomes were 30-day and 90-day in-hospital mortality. Kaplan-Meier analysis and multivariable Cox proportional hazards models assessed the association between MCHC and mortality.
Results:
Kaplan-Meier curves showed significant survival differences across MCHC quartiles, with higher MCHC associated with better survival. In fully adjusted Cox models, each unit increase in MCHC was associated with lower mortality risk at 30 days (HR: 0.86, 95% CI: 0.83-0.89) and 90 days (HR: 0.86, 95% CI: 0.83-0.88). Patients in the highest MCHC quartile had significantly lower mortality risk compared to the lowest quartile (30-day - HR: 0.56, 95% CI: 0.49-0.63; 90-day - HR: 0.55, 95% CI: 0.49-0.62). Subgroup analyses confirmed consistent associations across all clinical strata.
Conclusion:
Lower MCHC levels at ICU admission are independently associated with increased short-term and medium-term mortality in critically ill cancer patients.
